Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Orion Terminates ODM-111 Program Due To Narrow Therapeutic Window Challenges
Details : ODM-111 is NaV. 1.8 blocker was being evaluated in the early-stage clinical trial studies with the patients for the treatment of acute and chronic pain.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 24, 2024
Lead Product(s) : ODM-104,Paracetamol
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Blood-Brain Barrier Penetration of Therapeutic Agents in Human
Details : ODM-104 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Central Nervous System Diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 01, 2020
Lead Product(s) : ODM-104,Paracetamol
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetic of Levodopa Study in Healthy Males
Details : Levodopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 04, 2017
Pharmacokinetic Study in Healthy Volunteers
Details : Levodopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 18, 2015
Pharmacokinetic Study in Healthy Males
Details : Levodopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 09, 2014
Lead Product(s) : Levodopa,Carbidopa,Entacapone
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Levodopa Concentration Profile With Stalevo 75/125 mg
Details : Levodopa is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 18, 2010
Lead Product(s) : Levodopa,Carbidopa,Entacapone
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
